Quo vadis: Advanced prostate cancer—clinical care and clinical research in the era of multiple androgen receptor-directed therapies

Author： Kim Won   Ryan Charles J.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|3|361-371

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.3, 2015-02, pp. : 361-371

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

By  

Current Drug Targets, Vol. 17, Iss. 3, 2016-03 ,pp. : 290-302

Bentham Science Publishers

Access to resources Recommend Favorite

Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies: Incidence and Clinical Significance

By Paul R.   Breul J.  

Drug Safety, Vol. 23, Iss. 5, 2000-11 ,pp. : 381-390

Adis International

Access to resources Recommend Favorite

Chemokine Receptor-directed Agents as Novel Anti-HIV-1 Therapies

By  

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 10, 2004-06 ,pp. : 1017-1033

Bentham Science Publishers

Access to resources Recommend Favorite

Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate

By  

Medicinal Chemistry, Vol. 12, Iss. 5, 2016-08 ,pp. : 412-418

Bentham Science Publishers

Access to resources Recommend Favorite

Concept and viability of androgen annihilation for advanced prostate cancer

By Mohler James L.  

Cancer, Vol. 120, Iss. 17, 2014-09 ,pp. : 2628-2637

Blackwell Publishing

Access to resources Recommend Favorite